Osenvelt: Uses, Dosage & Side Effects

What Is Osenvelt and What Is It Used For?

Osenvelt contains the active substance denosumab, a fully human monoclonal antibody of the immunoglobulin G2 (IgG2) subclass produced in genetically engineered Chinese hamster ovary (CHO) cells using recombinant DNA technology. As a biosimilar medicine, Osenvelt has been developed to be highly similar to the reference product Xgeva (manufactured by Amgen), which was first approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in 2010 for oncology indications. The biosimilar pathway requires a rigorous stepwise demonstration of comparability, encompassing analytical characterization of the protein structure, functional assays of biological activity, nonclinical pharmacology and toxicology studies, and pharmacokinetic and pharmacodynamic confirmation in humans, with clinical efficacy and safety bridging where needed. The outcome is a biologic that is expected to perform identically to its reference product in clinical practice.

It is important to distinguish Osenvelt (denosumab 120 mg) from the 60 mg denosumab products used for osteoporosis (such as Prolia and its biosimilars). Although both contain the same active substance, they are supplied at different strengths, administered at different intervals, approved for different indications, and are not interchangeable. Osenvelt at 120 mg subcutaneously every 4 weeks delivers approximately twelve times the annual exposure of the 60 mg-every-6-months osteoporosis dose, reflecting the greater anti-resorptive demands of tumor-driven bone disease.

Denosumab exerts its therapeutic effect through a highly specific mechanism of action targeting the RANK–RANKL–OPG signaling pathway, the master regulator of osteoclast biology. In normal bone remodeling, receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed by osteoblasts, stromal cells, and osteocytes, and binds to its receptor RANK on osteoclast precursors and mature osteoclasts. This interaction is essential for osteoclast differentiation, activation, and survival. Osteoprotegerin (OPG) serves as the natural decoy receptor for RANKL, maintaining the physiological balance of bone resorption and formation. In advanced malignancy involving bone, tumor cells and their microenvironment produce pro-inflammatory cytokines and growth factors that markedly upregulate RANKL expression, shifting the balance toward aggressive osteoclast-mediated bone destruction. This produces the classic cycle of tumor-induced bone loss: tumor cells stimulate osteoclasts, osteoclast-mediated resorption releases growth factors stored in the bone matrix, and these factors in turn feed tumor cell proliferation—a self-perpetuating loop known as the “vicious cycle” of bone metastasis.

Denosumab mimics the natural action of OPG by binding to RANKL with high affinity and specificity, preventing RANKL from activating RANK on osteoclast surfaces. This effectively inhibits osteoclast differentiation, suppresses the bone-resorbing activity of mature osteoclasts, and promotes osteoclast apoptosis. The pharmacodynamic consequence is a rapid and profound decrease in bone resorption markers: in patients with bone metastases, serum concentrations of urinary N-telopeptide relative to creatinine (uNTx/Cr) decline by approximately 80% within one week of the first 120 mg dose and remain suppressed with continued therapy. This translates into fewer pathological fractures, fewer episodes of spinal cord compression, and less need for palliative radiation or surgery to bone.

Osenvelt is indicated for the following clinical situations where reducing pathological bone resorption provides significant benefit to patients with malignancy:

• Prevention of skeletal-related events in adults with advanced malignancies involving bone: This includes patients with bone metastases from solid tumors such as breast cancer, prostate cancer (particularly castration-resistant disease), non-small cell lung cancer, and other solid tumors, as well as patients with multiple myeloma. A skeletal-related event (SRE) is defined as a pathological fracture, radiation therapy to bone (often required for pain control), surgery to bone (such as stabilization of an impending fracture), or spinal cord compression. SREs are among the most debilitating complications of advanced cancer and are associated with substantial pain, reduced mobility, poorer quality of life, and increased mortality.
• Treatment of giant cell tumor of bone (GCTB): For adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. GCTB is a locally aggressive, osteolytic tumor characterized by a dense population of osteoclast-like multinucleated giant cells that express RANK and respond to RANKL. By neutralizing RANKL, denosumab halts the osteolytic activity of these giant cells, induces formation of new bone within the tumor, and produces dramatic radiographic and clinical responses that can enable less morbid surgery or obviate the need for surgery altogether.
• Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy: In some jurisdictions, the 120 mg dose is approved for the treatment of hypercalcemia of malignancy (HCM) that is refractory to bisphosphonate therapy. Denosumab provides a valuable option in this life-threatening complication, including for patients with renal impairment in whom intravenous bisphosphonates are contraindicated.

The clinical evidence supporting denosumab 120 mg comes from three large pivotal phase III randomized, double-blind, active-comparator trials that enrolled more than 5,700 patients and compared denosumab directly with zoledronic acid, the prior standard of care. In breast cancer with bone metastases (study 136), denosumab reduced the risk of the first on-study SRE by 18% compared with zoledronic acid (hazard ratio 0.82, 95% confidence interval 0.71–0.95, p=0.01 for superiority). In castration-resistant prostate cancer with bone metastases (study 103), denosumab reduced the risk of the first SRE by 18% (hazard ratio 0.82, 95% CI 0.71–0.95, p=0.008 for superiority). In patients with other solid tumors or multiple myeloma (study 244), denosumab demonstrated non-inferiority to zoledronic acid for the primary endpoint of time to first SRE. Across these trials, denosumab also delayed the development of moderate-to-severe pain and reduced the need for strong opioid analgesics, with a generally acceptable safety profile.

The evidence for giant cell tumor of bone comes from two open-label phase II studies (study 20040215 and study 20062004) that together enrolled more than 500 patients. Among evaluable patients, the objective tumor response rate exceeded 70%, with many responses characterized by dense new bone formation replacing the lytic tumor tissue, clinical improvements in pain and function, and in some cases conversion of unresectable disease into surgically manageable disease. These results established denosumab as a standard-of-care systemic therapy for unresectable GCTB and transformed the management of this uncommon but locally destructive bone tumor.

What Should You Know Before Taking Osenvelt?

Contraindications

Osenvelt is contraindicated in patients with severe, untreated hypocalcemia and in patients with known hypersensitivity to denosumab or to any of the excipients. Although rare, serious allergic reactions including anaphylaxis have been reported with denosumab products. Pre-existing hypocalcemia must be corrected before initiating therapy by adequate intake of calcium and vitamin D, with confirmation of normalized serum calcium. This is a critical safety requirement because denosumab's potent inhibition of osteoclast-mediated bone resorption sharply reduces calcium release from the skeleton; in patients who start therapy with borderline or low calcium levels, this can precipitate severe, symptomatic, and occasionally life-threatening hypocalcemia with cardiac arrhythmias, seizures, QT prolongation, laryngospasm, muscle spasms, and tetany. The risk is substantially higher with the 120 mg oncology dose than with the 60 mg osteoporosis dose.

Osenvelt is also contraindicated in patients with unhealed lesions from dental or oral surgery, since these lesions represent a window of vulnerability for developing osteonecrosis of the jaw. Before starting Osenvelt, your healthcare provider will typically perform a thorough medical assessment including measurement of serum calcium (corrected for albumin or ionized calcium), 25-hydroxyvitamin D, creatinine, phosphate, and magnesium levels, as well as review of dental health. Patients with conditions predisposing to hypocalcemia—including hypoparathyroidism, previous thyroid or parathyroid surgery, malabsorption syndromes, short bowel syndrome, severe renal impairment, or concurrent calcimimetic therapy—require particularly careful monitoring.

Warnings and Precautions

Hypocalcemia: Osenvelt can cause severe, symptomatic hypocalcemia. Fatal cases have been reported in post-marketing surveillance, particularly in patients with severe renal impairment or on dialysis. Serum calcium should be measured before each dose and at periodic intervals thereafter, with more intensive monitoring (within 7–10 days after the first dose) in patients at high risk. All patients must receive at least 500 mg of calcium and 400 IU of vitamin D daily unless they have pre-existing hypercalcemia. Patients with creatinine clearance less than 30 mL/min or on dialysis often require higher doses of calcium and activated vitamin D, and should have their calcium, phosphate, and magnesium closely monitored.

Osteonecrosis of the jaw (ONJ): ONJ is a well-recognized adverse effect of anti-resorptive therapy, and its incidence is higher with the 120 mg denosumab dose used in oncology than with the 60 mg dose used in osteoporosis. ONJ can present as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, gingival erosion, or persistent pain or slow healing of the mouth or jaw after dental surgery. In the pivotal oncology trials, the cumulative incidence of ONJ with denosumab over an approximately 3-year period was in the range of 1–2%, rising with longer exposure. Risk factors include invasive dental procedures (extraction, implant placement, oral surgery), poorly fitting dentures, poor oral hygiene, concomitant corticosteroids or chemotherapy, angiogenesis inhibitors, radiotherapy to the head and neck, smoking, and pre-existing dental disease. A dental examination with appropriate preventive dentistry and any needed invasive dental work should be completed, and mucosa fully healed, before starting Osenvelt. During treatment, patients should maintain excellent oral hygiene, receive routine dental check-ups, and avoid invasive dental procedures when possible.

Atypical femoral fractures: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with denosumab. These fractures may occur with minimal or no trauma, can be bilateral, and are frequently preceded by prodromal thigh, hip, or groin pain for weeks or months. Any patient on long-term denosumab who reports new hip, thigh, or groin pain should be evaluated with imaging to exclude an incomplete atypical fracture. The decision to continue or discontinue therapy should weigh the patient's fracture risk, metastatic disease status, and available alternatives.

Osteonecrosis of the external auditory canal: Rare cases of osteonecrosis of the external auditory canal have been reported with denosumab. Possible risk factors include steroid use, chemotherapy, infections, cotton bud use, and ear canal trauma. Ear symptoms such as chronic ear infections, otalgia, or otorrhea should be evaluated promptly in patients receiving denosumab.

Multiple vertebral fractures after discontinuation: In patients with osteoporosis, abrupt discontinuation of denosumab has been associated with rapid rebound bone resorption and multiple vertebral fractures. While this risk has been best characterized with the 60 mg osteoporosis dose, any transition off long-term denosumab therapy in oncology should be discussed in the context of the patient's bone health and overall prognosis, and may warrant consideration of sequential bisphosphonate therapy in selected cases.

Skin reactions: Dermatitis, eczema, and rashes have been reported with denosumab. Most are mild to moderate, but severe cases warranting treatment discontinuation have been reported.

Infections: In clinical trials, infections including serious skin infections (cellulitis and erysipelas) were reported more frequently with denosumab than with placebo. Patients on concomitant immunosuppressive therapy or with underlying immune compromise may be at higher risk. Patients should seek prompt medical attention for signs of infection, especially skin infections.

Suppression of bone turnover: Denosumab profoundly suppresses bone turnover, and the long-term consequences of this suppression are not completely understood. The possibility of over-suppression leading to atypical fractures, delayed fracture healing, or ONJ should be considered when planning long-duration therapy.

Pregnancy and Breastfeeding

Osenvelt is not recommended during pregnancy and women of reproductive potential must use highly effective contraception during treatment and for at least 5 months after the last dose of Osenvelt. There are no adequate, controlled human data on use of denosumab in pregnancy. Animal reproductive studies have demonstrated that denosumab can cross the placenta and cause significant adverse effects in the developing fetus, including absent peripheral lymph nodes, abnormal bone growth and architecture, reduced bone strength, abnormal tooth development and eruption, impaired postnatal growth, and reduced neonatal survival. Given that RANKL has critical roles in embryonic skeletal modeling, lymph node organogenesis, and mammary gland development, the potential for harm in a human fetus is considered substantial.

It is not known whether denosumab is excreted in human breast milk, but denosumab is an IgG antibody and IgG antibodies are known to be excreted in milk. Because of the potential for adverse effects on the breastfed infant—including possible effects on bone metabolism, tooth development, and immune development—breastfeeding is not recommended during treatment with Osenvelt and for at least 5 months after the last dose.

Fertility: There are no data on the effect of denosumab on human fertility. Animal studies of adult animals showed no adverse effects on female fertility. Patients considering future pregnancy should discuss fertility preservation strategies with their oncology team before initiating long-term therapy.

How Does Osenvelt Interact with Other Drugs?

As a fully human IgG2 monoclonal antibody, denosumab is catabolized via general protein degradation pathways rather than hepatic cytochrome P450 (CYP) enzymes. It does not inhibit, induce, or compete with CYP-mediated drug metabolism, and it is not a substrate, inhibitor, or inducer of drug transporters such as P-glycoprotein. Formal drug–drug interaction studies have not shown clinically significant pharmacokinetic interactions with commonly co-administered medications. For example, in patients with multiple myeloma, denosumab did not affect the pharmacokinetics or safety of midazolam (a CYP3A4 probe substrate) and did not alter exposure to common myeloma therapies such as lenalidomide and dexamethasone.

That said, a number of pharmacodynamic interactions and clinical considerations are important for patients receiving Osenvelt:

Major Interactions

The most clinically significant pharmacodynamic interactions involve concurrent use of denosumab with other bone-targeted agents. Concurrent use of denosumab with bisphosphonates is not recommended because both classes inhibit osteoclast-mediated bone resorption through different but overlapping mechanisms, and combined therapy could lead to over-suppression of bone turnover, increased risk of hypocalcemia, and potentially higher rates of ONJ and atypical fractures. If a change from bisphosphonate therapy to denosumab is clinically appropriate, a simple sequential switch without overlap is the standard approach.

The combination of denosumab with angiogenesis inhibitors (bevacizumab, sunitinib, sorafenib, and others) warrants particular caution because both classes have independently been associated with ONJ, and observational data suggest substantially higher rates when they are combined. Patients who require concurrent anti-resorptive and anti-angiogenic therapy for advanced cancer should be managed with particularly careful dental surveillance, pre-treatment dental optimization, and avoidance of invasive dental procedures during therapy whenever possible.

Calcimimetic agents such as cinacalcet, used to manage secondary hyperparathyroidism in patients on dialysis, can interact additively with denosumab to produce clinically significant hypocalcemia. Calcium should be monitored intensively in patients receiving both drugs, and calcimimetic doses may require adjustment or temporary discontinuation.

Minor Interactions

Denosumab does not appear to interact significantly with the vast majority of commonly used medications, including antihypertensives, statins, proton pump inhibitors, selective serotonin reuptake inhibitors (SSRIs), oral anti-diabetic medications, most anticoagulants, and most antibiotics. In clinical trials, denosumab has been used alongside a wide variety of concomitant medications in advanced cancer populations without evidence of clinically meaningful pharmacokinetic interactions.

Cancer immunotherapies (such as immune checkpoint inhibitors) are frequently co-prescribed with denosumab, and there is no clinically significant pharmacokinetic interaction. Some preclinical and observational data suggest possible additive anti-tumor effects, but this is not an established indication and should not influence clinical decision making outside of clinical trials.

Patients should always inform their healthcare team about all prescription medications, over-the-counter drugs, supplements, and herbal products they are taking before starting Osenvelt. While pharmacokinetic interactions are unlikely, the pharmacodynamic considerations summarized above are clinically important and should be discussed at each treatment review.

What Is the Correct Dosage of Osenvelt?

Osenvelt is supplied as a ready-to-use, clear colorless-to-pale-yellow solution for injection in a single-use vial containing 120 mg of denosumab in 1.7 mL (approximately 70 mg/mL). The dosing regimen is fixed and does not require routine adjustment based on body weight, age, sex, or renal function. Osenvelt must be administered under the supervision of a healthcare professional familiar with the management of cancer patients and bone-targeted therapies. Sterile technique should be used, and the vial should be inspected visually before withdrawal; the solution should be discarded if it is cloudy, discolored, or contains visible particles.

Adults: Prevention of Skeletal-Related Events in Advanced Cancer

Adults and Skeletally Mature Adolescents: Giant Cell Tumor of Bone

Children

Osenvelt at the 120 mg dose is approved for the treatment of giant cell tumor of bone in skeletally mature adolescents (those whose growth plates have closed). It is not recommended in children or adolescents who are still skeletally growing because RANKL plays a critical role in bone modeling, tooth development, and the formation of lymph nodes during growth, and denosumab inhibition could theoretically impair these processes. The safety and efficacy of denosumab in children below 12 years of age and in skeletally immature adolescents have not been established.

Elderly

No dose adjustment is required for elderly patients. In the pivotal oncology trials of the reference product, the efficacy and safety of denosumab were consistent across age subgroups. Elderly patients with advanced cancer may have additional comorbidities (such as renal impairment, dental disease, malnutrition, and polypharmacy) that warrant enhanced monitoring for hypocalcemia, infections, and ONJ.

Renal Impairment

No dose adjustment is required for any degree of renal impairment, since denosumab is a monoclonal antibody and is not cleared by the kidneys. This is an important advantage over intravenous bisphosphonates such as zoledronic acid, which require dose reduction below a creatinine clearance of 60 mL/min and are contraindicated below 30 mL/min. However, patients with creatinine clearance below 30 mL/min or on dialysis are at substantially increased risk of severe, symptomatic, and potentially fatal hypocalcemia with denosumab. These patients require intensive monitoring of calcium, phosphate, magnesium, and vitamin D; frequently require activated vitamin D (calcitriol or alfacalcidol) in place of or in addition to standard vitamin D; and may need higher calcium supplementation.

Hepatic Impairment

The pharmacokinetics of denosumab have not been formally studied in patients with hepatic impairment. Because denosumab is cleared by general protein catabolism rather than hepatic metabolism, clinically significant changes in exposure are not expected, and no dose adjustment is anticipated.

Missed Dose

If a dose of Osenvelt is missed or delayed, it should be administered as soon as possible. Thereafter, subsequent injections should be scheduled every 4 weeks from the date of the last injection. Short delays of a week or two are unlikely to have substantial clinical impact, but longer delays may allow bone turnover markers to rise and anti-resorptive protection to attenuate. Patients should maintain regular contact with their oncology team to ensure scheduled administration.

Overdose

There is no specific clinical experience with acute overdose of denosumab. In clinical pharmacology studies, denosumab has been administered at doses up to 180 mg every 4 weeks (50% higher than the licensed dose) without dose-limiting toxicity. There is no specific antidote. In the event of an overdose, the patient should be monitored for signs and symptoms of hypocalcemia and supportive care provided, including calcium supplementation as clinically indicated. Denosumab is not removed by dialysis because of its large molecular size.

What Are the Side Effects of Osenvelt?

The safety profile of denosumab 120 mg has been extensively characterized through three large phase III randomized controlled trials in advanced cancer (more than 5,700 patients), supporting open-label extension studies, dedicated GCTB trials, and extensive post-marketing surveillance worldwide. Adverse effects reported below reflect the combined experience with the reference product Xgeva and class effects of denosumab. Biosimilars such as Osenvelt are expected to have the same safety profile as the reference product. Frequencies are categorized according to the internationally recognized MedDRA convention. Because Osenvelt is used in patients with advanced cancer, many reported adverse events may reflect both the underlying disease, concurrent chemotherapy or radiotherapy, and denosumab itself.

Hypocalcemia is the most clinically important expected pharmacological consequence of potent anti-resorptive therapy with the 120 mg dose. In the pivotal phase III oncology trials, laboratory hypocalcemia (serum calcium below the lower limit of normal) occurred in approximately 10–13% of denosumab-treated patients compared with 5–6% of zoledronic acid-treated patients. Clinically significant, symptomatic hypocalcemia was less common, generally occurring in 1–4% of patients, and in almost all cases was preventable or manageable with adequate calcium and vitamin D supplementation. The risk of severe or fatal hypocalcemia is markedly higher in patients with severe renal impairment (CrCl <30 mL/min), those on dialysis, those with hyperphosphatemia, those not receiving or not adhering to calcium and vitamin D, and those on concurrent calcimimetics.

Osteonecrosis of the jaw (ONJ) is a recognized adverse effect of anti-resorptive therapy at oncology doses. In the pivotal trials, the cumulative incidence of ONJ over approximately 3 years was 1–2% with denosumab 120 mg every 4 weeks, compared with approximately 1.3% with zoledronic acid, with rates rising with longer exposure. Patients who develop ONJ typically present with exposed necrotic bone, persistent jaw pain, or non-healing of the oral mucosa after dental surgery. Management requires a coordinated approach involving oral and maxillofacial surgery, conservative dental care, and sometimes temporary discontinuation of anti-resorptive therapy.

Atypical femoral fractures are rare (<0.1%) but clinically significant. They typically present as new thigh, hip, or groin pain that may be bilateral and often precedes a complete fracture by weeks to months. Any patient on long-term Osenvelt who develops such symptoms should undergo prompt imaging of both femurs.

Hypercalcemia after discontinuation is a specific concern in patients with giant cell tumor of bone, particularly in skeletally mature adolescents and young adults. After stopping denosumab, a rebound increase in bone turnover can release calcium from bone rapidly, occasionally producing clinically significant hypercalcemia weeks to months after the last dose. Patients completing denosumab therapy for GCTB should be followed with periodic serum calcium measurements for several months after treatment ends.

Infusion-type and hypersensitivity reactions are uncommon but can be serious. Patients with known severe allergy should be monitored during administration. Dermatological reactions (rash, eczema, dermatitis, pruritus) are common but usually mild and can often be managed with topical therapy.

How Should You Store Osenvelt?

Proper storage of Osenvelt is essential to maintain the stability, potency, and safety of the biological product. As a protein-based monoclonal antibody, denosumab is sensitive to temperature extremes, vigorous physical agitation, and prolonged light exposure, all of which can lead to protein denaturation, aggregation, and loss of biological activity. Subvisible protein aggregates can also increase the theoretical risk of immune reactions, so storage conditions are not merely a quality matter but a safety matter.

The recommended storage conditions for Osenvelt are as follows:

• Refrigerated storage: Store at 2–8°C (36–46°F) in a refrigerator. This is the primary long-term storage condition and matches typical vaccine/biologic cold-chain logistics.
• Do not freeze: Freezing causes irreversible damage to the protein structure. If the product has been frozen, or if there is any doubt about whether it has been frozen, it should not be used and should be discarded.
• Protect from light: Keep the vial in the original outer carton until use to protect the solution from light exposure.
• Room-temperature allowance before administration: Before injection, Osenvelt may be removed from the refrigerator and allowed to reach room temperature (up to 25°C / 77°F) over approximately 15–30 minutes. A room-temperature injection is more comfortable and reduces the risk of injection site discomfort. Do not warm the vial by any other means (for example, microwave, hot water, direct sunlight, or placing on a heater).
• Single-use vial: Each vial contains enough solution for a single 120 mg dose. Any solution remaining in the vial after the dose is withdrawn should be discarded according to institutional and local regulations.
• Do not shake: Vigorous shaking can cause protein aggregation and foaming, reducing biological activity and potentially increasing immunogenicity.
• Shelf life: Refer to the expiry date printed on the carton and the vial label. Do not use Osenvelt after the expiry date, which refers to the last day of that month.
• Visual inspection: Before administration, visually inspect the solution. It should appear clear and colorless to pale yellow. Do not use if the solution is cloudy, discolored, or contains visible particles (other than trace translucent to white protein particles which are a known property of the product and addressed in the manufacturer's instructions).
• Sharps disposal: Used needles, syringes, and vials must be placed in an approved sharps disposal container and disposed of in accordance with local regulations. Do not dispose of medical sharps in household waste.

Keep Osenvelt out of the sight and reach of children. Because Osenvelt is administered by a healthcare professional, the clinic or pharmacy is typically responsible for cold-chain storage, transport, and disposal. If you or a caregiver transports the medicine between refrigerators, use an insulated container with cold packs and follow the manufacturer's excursion guidance.

What Does Osenvelt Contain?

Osenvelt is a clear, colorless to pale yellow solution supplied in a single-use vial. Understanding the full composition of the product is important for healthcare providers assessing potential allergenic components and for patients with known hypersensitivities to specific excipients.

Active Ingredient

The active ingredient is denosumab, a fully human immunoglobulin G2 (IgG2) monoclonal antibody with a molecular weight of approximately 147 kDa. Each single-use vial contains 120 mg of denosumab in 1.7 mL of solution, giving a final concentration of approximately 70 mg per mL. Denosumab is produced by recombinant DNA technology in a mammalian cell line (genetically engineered Chinese hamster ovary, CHO, cells) and is purified through a multi-step process that includes protein A affinity chromatography, virus inactivation, ion exchange chromatography, and ultrafiltration/diafiltration to yield a highly pure, consistent antibody.

Inactive Ingredients (Excipients)

The formulation is designed to stabilize the antibody and maintain its biological activity throughout shelf life under refrigerated conditions. It contains:

• Acetic acid, glacial: Buffering agent used to maintain the pH of the solution within the optimal range for protein stability.
• Sodium hydroxide: Used for pH adjustment to achieve the target formulation pH.
• Sorbitol (E420): A sugar alcohol serving as a stabilizer and tonicity agent that helps protect the protein from denaturation during storage and ensures the solution is isotonic with body fluids.
• Polysorbate 20: A non-ionic surfactant that prevents protein aggregation and adsorption to container surfaces during storage and handling.
• Water for injections: The solvent vehicle for the formulation.

Osenvelt does not contain preservatives, and therefore any unused portion of the vial must be discarded after the single dose is withdrawn. The product does not contain latex in any of the components that come into contact with the medicine, and it does not contain materials of animal origin other than the mammalian cell line (CHO cells) used for production, which is a well-characterized source used across many modern biological medicines. Patients with known hypersensitivity to any of the listed excipients should inform their healthcare provider before receiving the injection so that alternatives can be considered.

Appearance and Supply

Osenvelt is supplied as a clear, colorless to pale yellow solution in a Type I glass vial with a fluoropolymer-coated rubber stopper, an aluminum seal, and a flip-off cap. Each carton typically contains one vial. The exact pack configuration may vary by region and supplier. Always check the labeling and patient information leaflet supplied with your specific product.